enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Hold” from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received an average rating of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $12.6818.

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 price target (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 15th. Raymond James Financial downgraded enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target on the stock. in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded enGene from a “hold” rating to a “sell” rating in a report on Saturday, April 18th.

Institutional Investors Weigh In On enGene

Large investors have recently modified their holdings of the business. Privium Fund Management B.V. acquired a new stake in shares of enGene in the 4th quarter valued at $3,179,000. Braidwell LP bought a new position in shares of enGene in the 3rd quarter valued at $15,479,000. PFS Partners LLC lifted its stake in shares of enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after acquiring an additional 2,000 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in shares of enGene in the 3rd quarter valued at $76,000. Finally, Monashee Investment Management LLC lifted its stake in shares of enGene by 8.5% in the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.65 on Tuesday. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The company has a market cap of $110.53 million, a PE ratio of -0.73 and a beta of -0.29. The business’s 50 day moving average price is $4.80 and its two-hundred day moving average price is $7.38. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last posted its earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.11. On average, analysts predict that enGene will post -2.02 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.